If I had to identify a single bottleneck, I would say it is managing complexity rather than overcoming a specific operational constraint. The real challenge lies in aligning expectations about timelines with the realities of aseptic fill and finish operations. These processes require many independent activities to come together smoothly, and the level of coordination required is often overlooked.
Success depends on synchronising processes both upstream and downstream. Filling capacity is only one piece of the puzzle. Drug substance availability, analytical testing, visual inspection, logistics, and other supporting functions all play a critical role in maintaining reliable operations. Consistent execution depends on having the right capabilities aligned and available at the right time and at the right scale.
With high-potency and personalised therapies on the rise, how are you adapting lines for smaller, high-value batch runs?
High-potency compounds and personalised therapies are important developments in the industry. However, every manufacturer first needs to identify which market segments fit its strategy, infrastructure, and expertise. Not every trend automatically aligns with every business model.
From an operational perspective, these evolving modalities require clearly defined processes and increase the need for manufacturing environments that can efficiently support smaller, high-value batch sizes. At Vetter, we have established structured assessment processes for high-potency projects to evaluate factors such as containment requirements, operational impact, and long-term fit. At the same time, we continue to invest in flexible cleanroom technologies and manufacturing infrastructure to adapt to changing customer and market requirements.
Where are automation and robotics delivering the most immediate return on investment on the fill-finish floor?
Automation and robotics help reduce process variability and create more robust operations, particularly for repetitive activities such as material handling or equipment interactions. The value is not only in greater consistency and efficiency, but also in reducing the risk of deviations and delays.
Beyond individual processes, the real opportunity lies in linking automation with digital systems. As a CDMO, we see automation as part of a larger digitalisation strategy. Better access to process data enables faster decision-making, improved equipment utilisation, and more effective production planning. It is not about replacing people, but rather about creating additional predictable, efficient, and scalable manufacturing operations.
How do you balance speed to market with the stringent demands of modern contamination control strategies (CCS)?
I do not see speed and contamination control as opposing objectives. In fact, an effective contamination control strategy can support efficient development or commercial manufacturing by identifying risks early and enabling informed decisions from the outset.
The key is to view CCS as a holistic concept rather than a collection of individual measures. It includes facility and process design, environmental monitoring, personnel practices, material flow, risk management, and cleanroom technology. When these elements are integrated from the beginning, manufacturers can strengthen sterility assurance while also supporting efficient and reliable project execution.
What is one common mistake companies make when transitioning a drug product into aseptic processing?
I often see companies make the mistake of starting with a preferred result in mind before fully understanding the process required to achieve it. In most cases, they already have a clear vision of the final drug product and delivery system, whether that is an autoinjector, a prefilled syringe or another presentation format. However, factors such as viscosity, stability, formulation characteristics and dosing requirements can significantly influence what is feasible.
The most successful projects are those in which sponsors engage with their aseptic manufacturing partner early on and openly discuss expectations and constraints. Early scientific and technical collaboration helps to identify potential challenges, evaluate alternatives and align product ambitions with manufacturing realities. The sooner these discussions take place, the more options will be available to develop a robust and scalable solution.
Looking ahead, what tech innovation do you think will redefine sterile manufacturing over the next five years?
I believe the future belongs to connected manufacturing. The combination of artificial intelligence, digital technologies, and integrated production environments has the potential to change how sterile manufacturing is managed. The ability to connect equipment, processes, and data will create greater transparency, support decision-making, and help manufacturers anticipate challenges.
Automation and robotics will continue to play an important role, but their greatest value will come from being part of a connected manufacturing ecosystem that enables smarter and more predictable operations.
